Home

Welcome

This site is intended to provide online access to current, accurate, and unbiased scientific information about our products.

Search our medical database to obtain comprehensive summaries of the scientific literature (published and unpublished) and information on our products.

  1. Register or login to access the medical information database
  2. Make your selections in the search boxes below
Register or login to access the medical information database

The medical information contained on this website focuses on topics on products in the anti-infective, psychiatry, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology fields. Below are some of our main products.

11/07/12

Cardiovascular - XARELTO® (rivaroxaban) New Indication Approval

Xarelto Press Release November 2012

02/27/12

RISPERDAL CONSTA (risperidone) Long-Acting Injection Dear Healthcare Professional Letter

RISPERDAL CONSTA DHCP Letter February 2012

02/24/12

LEVAQUIN (levofloxacin) Dear Healthcare Professional Letter

LEVAQUIN DHCP Letter February 2012

01/03/12

DORIBAX (doripenem for injection) Dear Healthcare Professional Letter

DORIBAX DHCP Letter January 3, 2012

12/12/11

Oncology - DOXIL® (doxorubicin HCl liposome injection) – Supply Shortage Update

Doxil DHCP Letter 12/12/11

11/21/11

Oncology - DOXIL® (doxorubicin HCl liposome injection) – Supply Shortage Update

Doxil DHCP Letter 11/21/11

11/04/11

Cardiovascular - XARELTO® (rivaroxaban) New Indication Approval

Press Release: FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

06/24/11

Oncology/Nephrology - PROCRIT® (epoetin alfa) - ESA label update

PROCRIT ESA Letter 6/24/2011

06/21/11

Oncology - DOXIL® (doxorubicin HCl liposome injection) – Availability

Doxil DHCP Letter 6/21/11

06/16/11

Psychiatry – RISPERDAL® (risperidone)/Risperidone - Recall

Risperdal - Risperidone Recall Letter 06/16/11

Archived Postings

Janssen Products


Access comprehensive information on Risk Evaluation and Mitigation Strategies (REMS) for our products. A REMS is a strategy to manage a known or a potential serious risk associated with a drug or biological product.

Click on the Janssen product below for more information.


Click here for Medication Guides for other Janssen products


Additional Resources


Additional REMS resources and guidance documents are available from the U.S. Food and Drug Administration (FDA).

Click on the FDA resources below for more information.

Outcomes Tools

Access tools that may be utilized as an aid to understand current utilization patterns or as part of assessing quality improvement opportunities. Links to available software programs that may be downloaded for your use are available by selecting the therapeutic area of interest below:

Clinical Tools

Access tools to help improve patient care. Links to tools are available by selecting the therapeutic area of interest below.

Coming Soon!

Patient Assistance Program

Provides access to a variety of patient assistance programs that offer more than 1000 prescription medications and medical products for free or at a discount to those who qualify.

 

Contact Us

  • Call us at 1-800-JANSSEN
    (1-800-526-7736)

    to speak to a clinical expert regarding your question or to report a possible adverse event or product quality complaint.

  • COMING SOON!

    Connect Online

    to receive answers to questions and real-time presentations from a clinical expert.

    Start

  • Submit a Question

    via this web site

    Send